{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:28:48Z","timestamp":1793777328310,"version":"4.6.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Netherlands Organization for Health Research and Development","award":["10200012330006"],"award-info":[{"award-number":["10200012330006"]}],"id":[{"id":"https:\/\/ror.org\/01yaj9a77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Timely integration of palliative care is critical in the management of patients with glioblastoma. This study evaluated the frequency and determinants of potentially inappropriate care in the final 3 months of life on population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient characteristics and healthcare utilization were extracted from medical records for deceased patients diagnosed with glioblastoma, who survived at least 3 months after diagnosis and received routine care at a single tertiary hospital between January 2015 and February 2026. Potentially inappropriate care was defined as the proportion of patients with any of these indicators in the final 3 months of life: \u22652 emergency department visits, \u22652 hospital admissions, &amp;gt;14 consecutive hospitalization days, intensive care unit admission, chemotherapy administration, or in-hospital death. Logistic regression analyses were performed to identify factors associated with receiving potentially inappropriate care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 310 patients (median age 66 [IQR 56-72], 60% male), of whom 22% (n\u2009=\u200967\/310) received potentially inappropriate care in the final 3 months of life. Chemotherapy was the main driver (n\u2009=\u200958\/67, 87%), followed by \u22652 hospital admissions (n\u2009=\u200910\/67, 15%) and in-hospital death (n\u2009=\u20099\/67, 13%). Older patients (OR 0.97, 95% CI, 0.94-0.99) or those with an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter (OR 0.42, 95% CI, 0.23-0.75) were less likely to receive potentially inappropriate care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>One in 5 patients with glioblastoma received potentially inappropriate care at the end of life, predominantly through chemotherapy. Younger patients and those with methylated MGMT promoters were most affected. Identification of patients at risk may support targeted palliative care interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag198","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:45:32Z","timestamp":1787226332000},"page":"2597-2608","source":"Crossref","is-referenced-by-count":0,"title":["Potentially inappropriate care at the end of life in patients with glioblastoma: A single-center observational cohort study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6488-163X","authenticated-orcid":false,"given":"Robin M","family":"Pieterman","sequence":"first","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-2558","authenticated-orcid":false,"given":"Esm\u00e9e K J","family":"van der Poort","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C M","family":"Baas-Thijssen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-9933","authenticated-orcid":false,"given":"Matthijs","family":"van der Meulen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-3179","authenticated-orcid":false,"given":"Erik W","family":"van Zwet","sequence":"additional","affiliation":[{"name":"Center of Medical Statistics, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9003-6124","authenticated-orcid":false,"given":"Yvette M","family":"van der Linden","sequence":"additional","affiliation":[{"name":"Center of Expertise in Palliative Care, Leiden University Medical Center , Leiden,","place":["The Netherlands"]},{"name":"Department of Radiotherapy, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-9616","authenticated-orcid":false,"given":"Johan A F","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026110401525036300_noag198-B1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"Van den Bent","year":"2023","journal-title":"Lancet"},{"key":"2026110401525036300_noag198-B2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00520-013-2088-9","article-title":"The end-of-life phase of high-grade glioma patients: a systematic review","volume":"22","author":"Sizoo","year":"2014","journal-title":"Support Care Cancer"},{"key":"2026110401525036300_noag198-B3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1177\/02692163251344164","article-title":"End-of-life care experiences and long-term outcomes of bereaved neuro-oncology caregivers: a cross-sectional survey","volume":"39","author":"Meer","year":"2025","journal-title":"Palliat Med"},{"key":"2026110401525036300_noag198-B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/nop\/npaa040","article-title":"Determining medical decision-making capacity in brain tumor patients: why and how?","volume":"7","author":"Pace","year":"2020","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/nop045","article-title":"Symptoms and problems in the end-of-life phase of high-grade glioma patients","volume":"12","author":"Sizoo","year":"2010","journal-title":"Neuro Oncol"},{"key":"2026110401525036300_noag198-B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/nop\/npae056","article-title":"Prospective assessment of end-of-life symptoms and quality of life in patients with high-grade glioma","volume":"11","author":"Walbert","year":"2024","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/nop\/npaa077","article-title":"Caregiver perceptions of end-of-life care in patients with high-grade glioma","volume":"8","author":"Fortunato","year":"2021","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B8","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.wneu.2024.08.114","article-title":"Caregivers\u2019 perspective and burden of the end-of-life phase of patients with glioblastoma: a multicenter retrospective study","volume":"192","author":"Gulino","year":"2024","journal-title":"World Neurosurg"},{"key":"2026110401525036300_noag198-B9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00520-009-0735-y","article-title":"Differential palliative care issues in patients with primary and secondary brain tumours","volume":"18","author":"Ostgathe","year":"2010","journal-title":"Support Care Cancer"},{"key":"2026110401525036300_noag198-B10","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European association for neuro-oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B11","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026110401525036300_noag198-B12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-015-2885-4","article-title":"Factors associated with aggressive end of life cancer care","volume":"24","author":"Henson","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026110401525036300_noag198-B13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intqhc\/mzi061","article-title":"Evaluating claims-based indicators of the intensity of end-of-life cancer care","volume":"17","author":"Earle","year":"2005","journal-title":"Int J Qual Health Care"},{"key":"2026110401525036300_noag198-B14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1200\/JCO.2003.03.059","article-title":"Identifying potential indicators of the quality of end-of-life cancer care from administrative data","volume":"21","author":"Earle","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026110401525036300_noag198-B15","doi-asserted-by":"publisher","first-page":"e0273997","DOI":"10.1371\/journal.pone.0273997","article-title":"Trends in appropriateness of end-of-life care in people with cancer, COPD or with dementia measured with population-level quality indicators","volume":"18","author":"De Schreye","year":"2023","journal-title":"PLoS One"},{"key":"2026110401525036300_noag198-B16","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S1470-2045(17)30582-X","article-title":"Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care","volume":"18","author":"Rietjens","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jpainsymman.2016.12.331","article-title":"Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel","volume":"53","author":"Sudore","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":":","key":"2026110401525036300_noag198-B18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/neuonc\/noaf230","article-title":"Early palliative care for patients with glioblastoma: a randomized phase III clinical trial (EPCOG)","volume":"28","author":"Golla","year":"2026","journal-title":"Neuro Oncol"},{"key":"2026110401525036300_noag198-B19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/nop\/npaf050","article-title":"End-of-life care in patients with glioblastoma after early advance care planning","volume":"12","author":"Fritz","year":"2025","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJMp1908153","article-title":"Goal-Concordant Care - Searching for the holy grail","volume":"381","author":"Halpern","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110401525036300_noag198-B21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jpainsymman.2016.04.015","article-title":"Care consistency with documented care preferences: methodologic considerations for implementing the \"measuring what matters\" quality indicator","volume":"52","author":"Unroe","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2026110401525036300_noag198-B22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0269216317705099","article-title":"Developing indicators of appropriate and inappropriate end-of-life care in people with Alzheimer\u2019s disease, cancer or chronic obstructive pulmonary disease for population-level administrative databases: a RAND\/UCLA appropriateness study","volume":"31","author":"De Schreye","year":"2017","journal-title":"Palliat Med"},{"key":"2026110401525036300_noag198-B23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejca.2019.11.009","article-title":"The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: a randomised controlled trial","volume":"124","author":"Vanbutsele","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026110401525036300_noag198-B24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00520-023-08198-0","article-title":"Potentially inappropriate end-of-life care and its association with relatives\u2019 well-being: a systematic review","volume":"31","author":"Ham","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026110401525036300_noag198-B25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026110401525036300_noag198-B26","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/neuonc\/noaf043","article-title":"End-of-life care in glioblastoma: a population-based study","volume":"27","author":"Ellenbogen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026110401525036300_noag198-B27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026110401525036300_noag198-B28","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1136\/bmjspcare-2020-002302","article-title":"Inappropriate end-of-life cancer care in a generalist and specialist palliative care model: a nationwide retrospective population-based observational study","volume":"12","author":"Boddaert","year":"2022","journal-title":"BMJ Support Palliat Care"},{"key":"2026110401525036300_noag198-B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5334\/ijic.7504","article-title":"Potentially inappropriate end of life care and healthcare costs in the last 30 days of life in regions providing integrated palliative care in The Netherlands: a registration-based study","volume":"24","author":"Pereira","year":"2024","journal-title":"Int J Integr Care"},{"key":"2026110401525036300_noag198-B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040721","article-title":"Association between inappropriate end-of-life cancer care and specialist palliative care: a retrospective observational study in two acute care hospitals","volume":"16","author":"Boddaert","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026110401525036300_noag198-B31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11912-022-01210-6","article-title":"Easing the journey-an updated review of palliative care for the patient with high-grade glioma","volume":"24","author":"Crooms","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026110401525036300_noag198-B32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026110401525036300_noag198-B33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF00435979","article-title":"The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires","volume":"5","author":"Osoba","year":"1996","journal-title":"Qual Life Res"},{"key":"2026110401525036300_noag198-B34","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001","edition":"3rd ed."},{"key":"2026110401525036300_noag198-B35","doi-asserted-by":"publisher","first-page":"116064","DOI":"10.1016\/j.ejca.2025.116064","article-title":"The use of EORTC QLQ-C30 summary score in cancer research and its performance as compared with the EORTC QLQ-C30 global health\/quality of life scale: a systematic review and comparative analysis of effect sizes","volume":"231","author":"Scheepens","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026110401525036300_noag198-B36","volume-title":"R: A Language and Environment for Statistical Computing [Computer Program]","year":"2023"},{"key":"2026110401525036300_noag198-B37","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","article-title":"Glioma patient-reported outcome assessment in clinical care and research: a response assessment in neuro-oncology collaborative report","volume":"21","author":"Armstrong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026110401525036300_noag198-B39","author":"IKNL","year":"2026"},{"key":"2026110401525036300_noag198-B40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12904-023-01154-z","article-title":"Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study","volume":"22","author":"N\u00e5hls","year":"2023","journal-title":"BMC Palliat Care"},{"key":"2026110401525036300_noag198-B41","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1002\/cam4.4344","article-title":"Aggressiveness of care at end of life in patients with high-grade glioma","volume":"10","author":"Harrison","year":"2021","journal-title":"Cancer Med"},{"key":"2026110401525036300_noag198-B42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026110401525036300_noag198-B43","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026110401525036300_noag198-B45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11523-010-0153-6","article-title":"MGMT promoter methylation in malignant gliomas","volume":"5","author":"Riemenschneider","year":"2010","journal-title":"Target Oncol"},{"key":"2026110401525036300_noag198-B46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B47","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","article-title":"EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","volume":"15","author":"Weller","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026110401525036300_noag198-B48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/nop\/npw022","article-title":"Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care","volume":"4","author":"Hemminger","year":"2017","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11060-017-2487-8","article-title":"End of life care for glioblastoma patients at a large academic cancer center","volume":"134","author":"Kuchinad","year":"2017","journal-title":"J Neurooncol"},{"key":"2026110401525036300_noag198-B50","doi-asserted-by":"publisher","first-page":"e1586","DOI":"10.1093\/oncolo\/oyae159","article-title":"Current status of advance care planning, palliative care consultation, and end-of-life care in patients with glioblastoma in South Korea","volume":"29","author":"Suh","year":"2024","journal-title":"Oncologist"},{"key":"2026110401525036300_noag198-B51","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.jpainsymman.2021.02.030","article-title":"Measuring goal-concordant care in palliative care research","volume":"62","author":"Ernecoff","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2026110401525036300_noag198-B52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/nop\/npaf059","article-title":"Bevacizumab for symptomatic cerebral radiation necrosis after radiation of high-grade glioma or brain metastases - when and for whom?","volume":"12","author":"Kroon","year":"2025","journal-title":"Neurooncol Pract"},{"key":"2026110401525036300_noag198-B53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/nop\/npae091","article-title":"Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: secondary outcome of the randomized phase III EORTC 26101 study","volume":"12","author":"Dirven","year":"2025","journal-title":"Neurooncol Pract"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag198\/71335678\/noag198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2597\/71335678\/noag198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2597\/71335678\/noag198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:52:57Z","timestamp":1793775177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/11\/2597\/8831462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag198","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,23]]}}}